Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
Date:2/12/2013

lopment and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA in November 2012.  Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The global oligonucleotide synthesis ... 2019 from $1,070.7 million in 2014, growing at ... The global oligonucleotide synthesis market is categorized on ... users, and geography. The synthesized oligonucleotides segment is ... the oligonucleotide synthesis market during the forecast period, ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... The Quigley,Corporation (Nasdaq: QGLY ) today issued an ... Diabetic Peripheral Neuropathy by its wholly owned,subsidiary, Quigley Pharma, ... noted that over 100 subjects have been,enrolled, 52 subjects ... for the Phase IIB study designed to evaluate the ...
... VALLEY COTTAGE, New York, September 11 XTL,Biopharmaceuticals Ltd. ... hold a,conference call today, September 11, 2007, at 8:30 ... Bicifadine for the treatment of diabetic,neuropathic pain that was ... Bentsur, XTL,s Chief Executive Officer.,Participating on the call will ...
... DIEGO, Sept. 10 SGX Pharmaceuticals, Inc.,(Nasdaq: ... license and collaboration,agreement with Novartis focused on the ... of both first line and drug resistant,Chronic Myelogenous ... Novartis are progressing a number of,potential drug candidates, ...
Cached Biology Technology:Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 3Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:9/1/2014)... every child in the U.S. undergoes a battery of ... sickle cell disease. Thousands of children born in the ... and die from the disease each year. , ... least some of those deaths. , A Post-Doctoral ... lab of George Whitesides, the Woodford L. and Ann ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... life without light. They emit echolocation sounds and use the ... or prey. In their brains, they have a spatial map ... at Technische Universitt Mnchen (TUM) has shown for the first ... , Closer objects appear larger , When ... number of activated neurons in its brain increases. As a ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... , New research into the Earth,s paleoclimate history by ... Hansen suggests the potential for rapid climate changes this ... global warming is not abated. By looking at ... Hansen sought insight into a fundamental question raised by ...
... Gil and Rongchao Jin have successfully used NMR ... which could advance the development and use of ... Their approach offers a significant advantage over routine ... determine whether the nanoparticles exist in a both ...
... York, NYDecember 7, 2011Thanks to a new study ... able to diagnose in their offices non-periodic arrhythmiasnoninvasively ... arrhythmias include atrial and ventricular fibrillation, which are ... in some cases be life-threatening. Using ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 2Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 3New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2
Sphingosine 1-phosphate receptor Edg-1...
VAP-1 (S-13)...
Human SPARC-like 1 Biotinylated Affinity Purified PAb...
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... spectrometry. PGE2 is one of the primary ... of the most widely investigated prostaglandins. Its ...
Biology Products: